DK1192247T3 - Sphingosinkinaseenzym - Google Patents

Sphingosinkinaseenzym

Info

Publication number: DK1192247T3
Authority: DK; Denmark
Prior art keywords: present; mimetics; analogues; derivatives; sphingosine kinase
Prior art date: 1999-05-13

Application number

DK00926537T

Other languages

English (en)

Inventor

Stuart Maxwell Pitson

Brian Wolff Wattenberg

Pu Xia

Andrea Richard James D

Jennifer Ruth Gamble

Mathew Alexander Vadas

Original Assignee

Johnson & Johnson Pharm Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2000-05-12

Publication date

2006-07-31

1999-05-13 Priority claimed from AUPQ0339A external-priority patent/AUPQ033999A0/en

1999-07-08 Priority claimed from AUPQ1504A external-priority patent/AUPQ150499A0/en

2000-05-12 Application filed by Johnson & Johnson Pharm Res filed Critical Johnson & Johnson Pharm Res

2006-07-31 Application granted granted Critical

2006-07-31 Publication of DK1192247T3 publication Critical patent/DK1192247T3/da

Links

108010035597 sphingosine kinase Proteins 0.000 title abstract 2
230000001413 cellular effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK00926537T 1999-05-13 2000-05-12 Sphingosinkinaseenzym DK1192247T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPQ0339A AUPQ033999A0 (en)	1999-05-13	1999-05-13	Novel therapeutic molecules and uses thereof
AUPQ1504A AUPQ150499A0 (en)	1999-07-08	1999-07-08	Novel therapeutic molecules and uses thereof-II

Publications (1)

Publication Number	Publication Date
DK1192247T3 true DK1192247T3 (da)	2006-07-31

Family

ID=25646054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00926537T DK1192247T3 (da)	1999-05-13	2000-05-12	Sphingosinkinaseenzym

Country Status (11)

Country	Link
US (3)	US6730480B1 (da)
EP (1)	EP1192247B9 (da)
JP (1)	JP2002543831A (da)
KR (1)	KR100798375B1 (da)
AT (1)	ATE323153T1 (da)
CA (1)	CA2372541A1 (da)
DE (1)	DE60027295T2 (da)
DK (1)	DK1192247T3 (da)
ES (1)	ES2261200T3 (da)
NZ (1)	NZ515132A (da)
WO (1)	WO2000070028A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6649362B2 (en) *	1997-09-08	2003-11-18	Medvet Science Pty. Ltd.	Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6423527B1 (en)	1997-09-29	2002-07-23	Children's Hospital Medical Center Of Northern California	Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
JP2003512072A (ja) *	1999-10-28	2003-04-02	ワーナー−ランバート・カンパニー	ヒトスフィンゴシンキナーゼ遺伝子
AU3828301A (en) *	2000-02-14	2001-08-27	Curagen Corp	Novel sphingosine kinases
AUPQ744700A0 (en) *	2000-05-11	2000-06-01	Medvet Science Pty. Ltd.	A method of treatment and agents useful for same
US20080279841A1 (en) *	2000-06-28	2008-11-13	Medvet Science Pty Ltd.	Novel Therapeutic Molecular Variants And Uses Thereof
US6610534B2 (en)	2000-10-05	2003-08-26	Novartis Ag	Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
CA2432978C (en)	2000-12-22	2012-08-28	Medlyte, Inc.	Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20050100547A1 (en) *	2001-06-07	2005-05-12	Pu Xia Etal	Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
JP4667749B2 (ja) *	2002-01-17	2011-04-13	チルドレンズホスピタルアンドリサーチセンターアットオークランド	スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
US7674580B2 (en)	2002-01-17	2010-03-09	Children's Hospital & Research Center At Oakland	Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
JP2005526809A (ja) *	2002-03-28	2005-09-08	メドベットサイエンスピーティーワイ．リミティッド	細胞活性を調節する方法
MXPA05003974A (es) *	2002-10-14	2005-08-03	Medvet Science Pty Ltd	Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
US20080050832A1 (en) *	2004-12-23	2008-02-28	Buechler Kenneth F	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060270631A1 (en) *	2005-05-26	2006-11-30	Smith Charles D	Methods for the treatment and prevention of angiogenic diseases
AU2006299417A1 (en) *	2005-10-03	2007-04-12	Biosite Incorporated	Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US9217749B2 (en)	2006-05-31	2015-12-22	Lpath, Inc.	Immune-derived moieties reactive against lysophosphatidic acid
PL2087002T3 (pl)	2006-10-27	2015-02-27	Lpath Inc	Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US20090004755A1 (en) *	2007-03-23	2009-01-01	Biosite, Incorporated	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) *	2007-03-23	2012-07-17	Seok-Won Lee	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8778614B2 (en)	2010-08-24	2014-07-15	Enzo Life Sciences, Inc.	Assays for detecting modified compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998054963A2 (en) *	1997-06-06	1998-12-10	Human Genome Sciences, Inc.	207 human secreted proteins
US6525174B1 (en) *	1997-06-06	2003-02-25	Human Genome Sciences, Inc.	Precerebellin-like protein
AUPO900297A0 (en) *	1997-09-08	1997-10-02	Medvet Science Pty. Ltd.	A method of modulating cellular activity
CA2329124A1 (en)	1998-05-26	1999-12-02	Office Of The Dean Of Research And Graduate Education	Sphingosine kinase, cloning, expression and methods of use
GB9816030D0 (en) *	1998-07-22	1998-09-23	Smithkline Beecham Plc	Novel compounds
AU2899900A (en) *	1999-03-02	2000-09-21	Nps Allelix Corp.	Cloned human sphingosine kinase homologues
JP2002538827A (ja) *	1999-03-18	2002-11-19	インサイト・ファーマスーティカルズ・インコーポレイテッド	細胞内リン酸化反応のレギュレータ
US6610534B2 (en) *	2000-10-05	2003-08-26	Novartis Ag	Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

2000
- 2000-05-12 KR KR1020017014462A patent/KR100798375B1/ko not_active Expired - Fee Related
- 2000-05-12 AT AT00926537T patent/ATE323153T1/de active
- 2000-05-12 DK DK00926537T patent/DK1192247T3/da active
- 2000-05-12 CA CA002372541A patent/CA2372541A1/en not_active Abandoned
- 2000-05-12 US US09/959,897 patent/US6730480B1/en not_active Expired - Lifetime
- 2000-05-12 ES ES00926537T patent/ES2261200T3/es not_active Expired - Lifetime
- 2000-05-12 NZ NZ515132A patent/NZ515132A/en not_active IP Right Cessation
- 2000-05-12 EP EP00926537A patent/EP1192247B9/en not_active Expired - Lifetime
- 2000-05-12 JP JP2000618434A patent/JP2002543831A/ja active Pending
- 2000-05-12 WO PCT/AU2000/000457 patent/WO2000070028A1/en not_active Ceased
- 2000-05-12 DE DE60027295T patent/DE60027295T2/de not_active Expired - Lifetime
2003
- 2003-08-18 US US10/642,289 patent/US7112427B2/en not_active Expired - Lifetime
2006
- 2006-09-26 US US11/526,708 patent/US20070071752A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040132053A1 (en)	2004-07-08
WO2000070028A1 (en)	2000-11-23
US6730480B1 (en)	2004-05-04
US7112427B2 (en)	2006-09-26
ATE323153T1 (de)	2006-04-15
NZ515132A (en)	2005-01-28
EP1192247B9 (en)	2007-10-31
EP1192247A4 (en)	2003-05-28
JP2002543831A (ja)	2002-12-24
EP1192247A1 (en)	2002-04-03
CA2372541A1 (en)	2000-11-23
DE60027295D1 (de)	2006-05-24
US20070071752A1 (en)	2007-03-29
DE60027295T2 (de)	2007-01-18
ES2261200T3 (es)	2006-11-16
KR100798375B1 (ko)	2008-01-28
KR20020000805A (ko)	2002-01-05
EP1192247B1 (en)	2006-04-12

Publication	Publication Date	Title
DK1192247T3 (da)	2006-07-31	Sphingosinkinaseenzym
DE69738581D1 (de)	2008-04-30	Menschliche dnase i hyperaktive varianten
ATE286053T1 (de)	2005-01-15	Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
PL377553A1 (pl)	2006-02-06	Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
AU2003266214A1 (en)	2004-04-19	Human coagulation factor vii polypeptides
TW200407425A (en)	2004-05-16	Human coagulation factor VII polypeptides
DE69435307D1 (de)	2010-09-16	Bazillus Thuringiensis und dessen insektizide Proteine
DE60137978D1 (de)	2009-04-23	Zusammensetzung zur förderung des haarwachstums
EP1100815A4 (en)	2005-05-25	PROTEASE TYPE II CLEAVABLE PEPTIDE
DE69534180D1 (de)	2005-06-02	Promotor der tie rezeptor protein kinase
ATE318328T1 (de)	2006-03-15	Diagnostika und therapeutika für osteoporose
WO2000053776A3 (en)	2000-12-14	Human kallikrein-like genes
DE60214867D1 (en)	2006-11-02	Histonedeacetylase 9
DK1339853T3 (da)	2006-11-13	Isolerede luciferaser og deres anvendelse
DE69737457D1 (de)	2007-04-19	O-fukosyltransferase
MXPA02007787A (es)	2004-09-10	Moleculas trade y uso relacionado con las mismas.
DE60120187D1 (de)	2006-07-06	Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1383871A4 (en)	2005-11-02	INSULATED HUMAN ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE PROTEINS, AND USES THEREOF
EP1383908A4 (en)	2005-06-22	ISOLATED HUMAN ENZYME PROTEINS, HUMAN ENZYME PROTEIN CODING NUCLEIC ACID MOLECULES, AND USES THEREOF
WO2003012102A3 (fr)	2004-04-08	Acides nucleiques codant des proteines a domaine hect
AU2002254438A1 (en)	2002-10-15	Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
MXPA02012924A (es)	2004-07-30	Nuevas variantes moleculares terapeuticas y sus usos.
WO2005049818A3 (en)	2006-01-05	Genes encoding human deubiquitinating enzymes
EP1383876A4 (en)	2005-10-12	ISOLATED HUMAN ENZYME PROTEINS, HUMAN ENZYME PROTEIN CODING NUCLEIC ACID MOLECULES, AND USES THEREOF
WO2001025430A3 (en)	2001-10-18	Novel human membrane proteins